Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, good morning and welcome to Taysha Jean Therapy's second quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. A brief question and answer session will follow the formal presentation. If anyone requires operator assistance during the conference, please signal the operator by pressing star and zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Haley Collins, Director, Head of Corporate Communications. Please go ahead. Thank you. Good morning and welcome to our second quarter 2025 financial results and corporate update conference call. Earlier today, Tayshia issued a press release announcing financial results for the second quarter ended June 30th, 2025. A copy of this press release is available on the company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Tayshia's Chief Executive Officer, Dukumar Nagandran, President and Head of R&D, Cameron Alam, Chief Financial Officer, and Dr. Elsa Rosignol, Director of the Integrated Rett Syndrome Clinic at St. Justine in Montreal and Principal Investigator of the Reveal Phase 1-2 Trials. We will be presenting slides to accompany our prepared remarks today, which will be available on our website after the call. We will host a question and answer session following our prepared remarks. Please note that Dr. Rosignol will be available to take questions until 9.20 a.m. Eastern Time, after which she will be stepping away for her clinic commitments. On today's call, we will be making forward-looking statements, including statements concerning the potential of TASHA-102, including the reproducibility and durability of any favorable results initially seen in patients...